Biomm, a Brazilian biotechnology company, concluded on May 16 an exclusive agreement with the Chinese Kexing Biopharm Co. Ltd. for licensing, commercialization and distribution of the biosimilar drug liraglutide in Brazil. The agreement is important for Biomm's growth strategy, which is based on diversifying the portfolio to serve several therapeutic areas.

To begin importing, distributing and marketing liraglutide in the country, Biomm still needs approval for registration with the National Health Surveillance Agency (Anvisa), publication of the price by the Medicines Market Regulation Chamber (CMED) and the end of the patent.

The hormone, which is a substance in the GLP-1 analog class, is used to treat type 2 diabetes and control weight in people who are obese or overweight.

According to Biomm's CEO, Heraldo Marchezini, with the agreement, the company continues to expand its portfolio and contribute to greater access for the population to medicines aimed at chronic diseases.

(Source: Diário do Comércio, on May 16)